Phase II clinical trial - Pédiatrie Tumeurs solides

MK-7902-013
Pédiatrie Tumeurs solides
Ouvert depuis le: 09.17.2021
Site: Paris
Public cible
Enfant
A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080) (E7080-G000-231)
Description de l'essai

The main purpose of this study is to evaluate the antitumor activity and safety of Lenvatinib (MK-7902/E7080) in children, adolescents, and young adults with relapsed or refractory solid malignancies after administration. Participants will be enrolled into initial tumor-specific cohorts which will be expanded based on observed response.